Abstract
Behavioral sciences are inseparably related to genetics. A variety of neurobehavioral phenotypes are suggested to result from genomic variations. However, the contribution of genetic factors to common behavioral disorders (i.e. autism, schizophrenia, intellectual disability) remains to be understood when an attempt to link behavioral variability to a specific genomic change is made.
Probably, the least appreciated genetic mechanism of debilitating neurobehavioral disorders is somatic mosaicism or the occurrence of genetically diverse (neuronal) cells in an individual’s brain. Somatic mosaicism is assumed to affect directly the brain being associated with specific behavioral patterns.
As shown in studies of chromosome abnormalities (syndromes), genetic mosaicism is able to change dynamically the phenotype due to inconsistency of abnormal cell proportions. Here, we hypothesize that brain-specific postzygotic changes of mosaicism levels are able to modulate variability of behavioral phenotypes. More precisely, behavioral phenotype variability in individuals exhibiting somatic mosaicism might correlate with changes in the amount of genetically abnormal cells throughout the lifespan. If proven, the hypothesis can be used as a basis for therapeutic interventions through regulating levels of somatic mosaicism to increase functioning and to improve overall condition of individuals with behavioral problems.
Keywords: Behavior, Brain, Chromosome, Somatic mosaicism, Postzygotic changes, Neurobehavioral disorders.
Current Genomics
Title:Behavioral Variability and Somatic Mosaicism: A Cytogenomic Hypothesis
Volume: 19 Issue: 3
Author(s): Svetlana G. Vorsanova, Maria A. Zelenova , Yuri B. Yurov and Ivan Y. Iourov*
Affiliation:
- Separated Structural Unit “Clinical Research Institute of Pediatrics at Pirogov Russian National Research Medical University named after Y.E Veltishev”, Ministry of Health of Russian Federation, Moscow 125412,Russian Federation
Keywords: Behavior, Brain, Chromosome, Somatic mosaicism, Postzygotic changes, Neurobehavioral disorders.
Abstract: Behavioral sciences are inseparably related to genetics. A variety of neurobehavioral phenotypes are suggested to result from genomic variations. However, the contribution of genetic factors to common behavioral disorders (i.e. autism, schizophrenia, intellectual disability) remains to be understood when an attempt to link behavioral variability to a specific genomic change is made.
Probably, the least appreciated genetic mechanism of debilitating neurobehavioral disorders is somatic mosaicism or the occurrence of genetically diverse (neuronal) cells in an individual’s brain. Somatic mosaicism is assumed to affect directly the brain being associated with specific behavioral patterns.
As shown in studies of chromosome abnormalities (syndromes), genetic mosaicism is able to change dynamically the phenotype due to inconsistency of abnormal cell proportions. Here, we hypothesize that brain-specific postzygotic changes of mosaicism levels are able to modulate variability of behavioral phenotypes. More precisely, behavioral phenotype variability in individuals exhibiting somatic mosaicism might correlate with changes in the amount of genetically abnormal cells throughout the lifespan. If proven, the hypothesis can be used as a basis for therapeutic interventions through regulating levels of somatic mosaicism to increase functioning and to improve overall condition of individuals with behavioral problems.
Export Options
About this article
Cite this article as:
Vorsanova G. Svetlana , Zelenova A. Maria , Yurov B. Yuri and Iourov Y. Ivan*, Behavioral Variability and Somatic Mosaicism: A Cytogenomic Hypothesis, Current Genomics 2018; 19 (3) . https://dx.doi.org/10.2174/1389202918666170719165339
DOI https://dx.doi.org/10.2174/1389202918666170719165339 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Iron Chelating Strategies in Systemic Metal Overload, Neurodegeneration and Cancer
Current Medicinal Chemistry Editorial [Hot topic: Role of Inflammation in Neurological and Psychiatric Disorders (Guest Editor: Mohtashem Samsam)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Functional Interactions of Tau and their Relevance for Alzheimers Disease
Current Alzheimer Research Ureas: Applications in Drug Design
Current Medicinal Chemistry Emerging Proof of Protein Misfolding and Interactions in Multifactorial Alzheimer's Disease
Current Topics in Medicinal Chemistry Novel Treatment Strategies for the Nervous System: Circadian Clock Genes, Non-coding RNAs, and Forkhead Transcription Factors
Current Neurovascular Research Targeting NO/cGMP Signaling in the CNS for Neurodegeneration and Alzheimer’s Disease
Current Medicinal Chemistry Humanin: A Possible Linkage Between Alzheimer’s Disease and Type 2 Diabetes
CNS & Neurological Disorders - Drug Targets Mesenchymal Stem Cells as a Source of Dopaminergic Neurons: A Potential Cell Based Therapy for Parkinson's Disease
Current Stem Cell Research & Therapy Complex Polyamines: Unique Prion Disaggregating Compounds
CNS & Neurological Disorders - Drug Targets HSP27: Mechanisms of Cellular Protection Against Neuronal Injury
Current Molecular Medicine Transmembrane Protein 166 and its Significance
Protein & Peptide Letters Small Molecule Inhibitors of NF-κB and JAK/STAT Signal Transduction Pathways as Promising Anti-Inflammatory Therapeutics
Mini-Reviews in Medicinal Chemistry Anti-Acetylcholinesterase Derivatives: A Privileged Structural Framework in Drug Discovery to Treat Alzheimer’s Disease
Current Enzyme Inhibition Reserve Mechanisms in Neurodegenerative Diseases: From Bench to Bedside and Back Again
Current Medicinal Chemistry Adult Neurogenesis in the Hypothalamus: Evidence, Functions and Implications
CNS & Neurological Disorders - Drug Targets The Protective Effects of Crocetin on Aβ<sub>1-42</sub>-Induced Toxicity in Ht22 Cells
CNS & Neurological Disorders - Drug Targets Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry The Multiple Layers of Signaling Selectivity at Protease-Activated Receptors
Current Pharmaceutical Design Epigenetic Regulation of Memory-Therapeutic Potential for Disorders
Current Neuropharmacology